Waters (WAT) is back in focus after first quarter 2026 results beat expectations, aided by strong organic growth and the BD Biosciences and Diagnostic Solutions acquisitions, alongside higher full year 2026 financial guidance.

Investors have responded quickly to the upgraded 2026 guidance, with the stock delivering a 17.64% 7 day share price return and an 8.60% 90 day share price return. However, year to date the share price return is down 7.02%, while the 1 year total shareholder return is down 3.15%. This leaves the recent rally set against a more mixed longer term picture.

If strong earnings reactions catch your eye, this could be a good moment to look beyond Waters and hunt for other potential movers using the 34 healthcare AI stocks

So with Waters trading at US$355.13, sitting at a reported intrinsic discount and below the average analyst price target, should you see this as a genuine entry point, or accept that the market is already pricing in future growth?

Most Popular Narrative: 9.7% Undervalued

At a last close of $355.13 versus a narrative fair value of $393.14, the most followed view sees Waters as modestly undervalued, hinging on a step change in growth and margins over time.

Waters is poised to benefit from robust growth in pharmaceutical R&D, evidenced by strong double-digit pharma segment expansion, increased instrument replacement cycles, and deeper penetration into high-growth areas like CDMOs and generics; this supports sustained revenue growth and pricing power as new product launches gain traction.

Curious what earnings path could support this higher fair value, even after recent share price gains? The narrative leans on faster top line expansion, a different margin mix, and a richer future earnings multiple than the broader Life Sciences sector.

Result: Fair Value of $393.14 (UNDERVALUED)

However, this narrative still faces real tests, including integration risk around the BD Biosciences and Diagnostic Solutions deal and pressure from weaker academic and government demand.

Another View: Expensive on Earnings

That 9.7% “undervalued” fair value story runs into a very different picture when you look at earnings. Waters trades on a P/E of 77.5x, compared with a fair ratio of 27.4x, the Global Life Sciences industry at 36.5x and peers at 28.8x, which points to clear valuation risk if sentiment cools.

Before leaning too heavily on any single approach, it is worth stress testing these earnings-based signals against your own assumptions, especially if you think the market could drift closer to the fair ratio over time, or hold its current premium for longer. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals across price, growth and valuation, it is worth checking the underlying data yourself and forming a clear stance quickly. To weigh both the potential upside and the downside that others are watching, start with the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If you only stop at Waters, you could miss out on other opportunities that fit your style, so put a few targeted stock screens to work for you.

• Spot potential bargains by scanning for companies that combine quality fundamentals with attractive pricing through the 49 high quality undervalued stocks.
• Prioritise resilience by reviewing stocks that score well on stability using the 71 resilient stocks with low risk scores.
• Hunt for underfollowed opportunities by checking a screener containing 21 high quality undiscovered gems before the crowd pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.